ReportsnReports – Market and Product Forecasts: Top 20 Oncology Therapy Brands – The Value of the Top 20 Decreases As the Oncology Market Fragments
The high level of commercial success experienced by the key companies in the oncology market makes it extremely attractive to drug developers. However, the shift toward a more personalized approach means fewer drugs will achieve blockbuster status. The evolution of a fragmented oncology market will decrease the value of the top 20 branded therapies by $8.6 billion between 2010 and 2020.
View full press release